Form D · Biotechnology

Inhalon Biopharma, Inc.

Carrboro, NC · CIK 0001822334

Offering snapshot reported Sep 17, 2020 · SEC filing

Reported sold
$2.9M
Offering amount: $3.63M
Investors reported
15
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Aug 18, 2020
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$1.45M$2.9MAug 26, 2020: $1,991,225.00Aug 26, 2020Sep 17, 2020: $2,903,725.00Sep 17, 2020

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$1,991,225 → $2,903,725
  • Reported investors13 → 15

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Sep 17, 2020Amendment$2,903,725$912,500vs Aug 26, 202015SEC filing
Aug 26, 2020Initial$1,991,225No comparison13SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-374195

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Kim, Hyun TaeNone

Source: Form D, filed Sep 17, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Samuel Lai Director, Executive
Winnie Wan Director
John B. Whelan Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
106 Oak Spring Court
Carrboro, NC, 27510